{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-22-090711","form_type":"8-K","ticker":"PTPI","cik":"0001815903","company_name":"Petros Pharmaceuticals, Inc.","filed_at":"2022-08-15T23:59:59+00:00","discovered_at":"2026-05-14T18:03:57.172294+00:00","generated_at":"2026-06-24T00:01:15.155582+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Petros Pharmaceuticals reports Q2 net sales of $4.2M, first positive adjusted EBITDA of $0.2M","bullets":["Q2 net sales of $4.2M, up 68% from $2.5M in Q2 2021; net loss narrowed to $1.8M from $2.1M.","First positive adjusted EBITDA of $0.2M, compared to negative $2.0M in prior-year period.","Prescription Medicines segment (STENDRA) sales up 102% YoY to $3.3M; gross margin stable at 84%.","Cash balance $13.3M as of June 30, 2022, down from $17.7M at March 31, 2022.","Announced positive OTC label comprehension study for STENDRA and pursuit of 505(b)(2) pathway for H-100 for Peyronie's disease."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-22-090711","json":"https://secwatch.observer/filing/0001104659-22-090711.json","markdown":"https://secwatch.observer/filing/0001104659-22-090711.md","text":"https://secwatch.observer/filing/0001104659-22-090711.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1815903/000110465922090711/0001104659-22-090711-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1815903/000110465922090711/tm2223325d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-24T00:01:15.155582+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}